Rheumatoid Arthritis Fibroblast-like Synoviocyte Suppression Mediated by PTEN Involves Survivin Gene Silencing

Danna Chen1,2, Dongdong Liu2, Dan Liu2

  • 1Department of Laboratory Science, Zengcheng District People's Hospital of Guangzhou (BoJi-Affiliated Hospital of Sun Yat-sen University), Guangzhou, 511300, China.

Scientific Reports
|March 25, 2017
PubMed

Insights

This study reveals that PTEN suppresses survivin, a key protein in rheumatoid arthritis (RA) fibroblast-like synoviocytes (RA-FLS). This finding suggests PTEN-based therapies could be a novel treatment for RA joint damage.

Area of Science:

  • Molecular Biology
  • Immunology
  • Rheumatology

Background:

  • Survivin, a proto-oncogene, promotes cell survival and proliferation via the PI3K/Akt pathway.
  • In rheumatoid arthritis (RA), elevated survivin correlates with severe joint damage and poor treatment outcomes.
  • The role of PTEN, a PI3K antagonist, in regulating survivin in RA remains unclear.

Purpose of the Study:

  • To investigate the effect of PTEN on survivin gene expression in RA fibroblast-like synoviocytes (RA-FLS).
  • To elucidate the interplay between PTEN and survivin in the context of RA pathogenesis.

Main Methods:

  • Primary RA-FLS were utilized to examine PTEN's influence on survivin expression.
  • Gene expression analysis was performed to quantify survivin levels following PTEN modulation.

Main Results:

  • PTEN was found to suppress survivin gene expression in RA-FLS.
  • This suppression by PTEN was identified as the mechanism mediating the inhibition of RA-FLS proliferation.
  • The study demonstrated PTEN-mediated survivin silencing in RA-FLS for the first time.

Conclusions:

  • PTEN plays a critical role in regulating survivin expression in RA pathogenesis.
  • Targeting PTEN could represent a novel therapeutic strategy for managing rheumatoid arthritis.
  • Survivin suppressants, potentially acting through PTEN, may offer new treatment avenues for RA patients.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.0K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K